Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Long-Term Investments: 2020-2023

Historic Long-Term Investments for Oncology Institute (TOI) over the last 4 years, with Q2 2023 value amounting to $58.9 million.

  • Oncology Institute's Long-Term Investments changed N/A to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $58.9 million, marking a year-over-year change of. This contributed to the annual value of $58.4 million for FY2022, which is N/A changed from last year.
  • As of Q2 2023, Oncology Institute's Long-Term Investments stood at $58.9 million.
  • In the past 5 years, Oncology Institute's Long-Term Investments ranged from a high of $230.3 million in Q1 2021 and a low of $58.2 million during Q3 2022
  • In the last 4 years, Oncology Institute's Long-Term Investments had a median value of $230.0 million in 2021 and averaged $167.8 million.
  • As far as peak fluctuations go, Oncology Institute's Long-Term Investments grew by 11.19% in 2021, and later crashed by 7469.05% in 2022.
  • Oncology Institute's Long-Term Investments (Quarter) stood at $230.3 million in 2020, then decreased by 0.1% to $230.0 million in 2021, then tumbled by 74.63% to $58.4 million in 2022, then grew by 1.01% to $58.9 million in 2023.
  • Its Long-Term Investments stands at $58.9 million for Q2 2023, versus $58.8 million for Q1 2023 and $58.4 million for Q4 2022.